

OFFICIAL

PATENT APPLICATION
ATTORNEY DOCKET NO. 22398

IN THE UNITED STATES PATENT & TRADEMARKS OFFICE

RECEIVED
CENTRAL FAX CENTERART UNIT: ~~3700~~ 3600

EXAMINER: Tejash Patel

APPLICANT: Dane J. Dickson

SERIAL NO.: ~~40/703,066~~ 10/763,066


FILED: 1/21/2004

CONFRM. NO.:

FOR: SYSTEMS AND METHODS FOR
SUCCINCTLY PRESENTING CLINICAL
TRIAL INFORMATIONCERTIFICATE OF MAILING
UNDER 37 C.F.R. § 1.8

DATE OF DEPOSIT: 5/7/04

I hereby certify that this paper or fee (along with any paper or fee referred to as being attached or enclosed) is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated above and is addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.


Gary P. Oakeson

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir/Madam:

Please find, pursuant to 37 C.F.R. § 1.98(a)(1), the enclosed Form PTO-1449 which contains a list of all patents, publications, or other items that have come to the attention of one or more of the individuals designated in 37 C.F.R. § 1.56(c). Applicant respectfully submits that this Information Disclosure Statement is filed pursuant to:

☒ 37 C.F.R. § 1.97 (b)(1) or (3), within three months of the filing date of the application, or before a first office action on the merits, whichever occurs last;

☐ 37 C.F.R. § 1.97 (c), after a first office action on the merits, but before a Final Office Action or a Notice of Allowance, whichever occurs first, and is accompanied by either 1) a statement in accordance with 37 C.F.R. § 1.97(e), or 2) the fee set forth in § 1.17(p); or

☐ 37 C.F.R. § 1.97 (d), after a Final Office Action or Notice of Allowance, whichever occurs first, but on or before payment of the issue fee, and is accompanied by both 1) a statement in accordance with 37 C.F.R. § 1.97(e), and 2) the fee set forth in § 1.17(p).

While no representation is made that any of these references may be "prior art" within the meaning of that term in accordance with 35 U.S.C. §§ 102 or 103, the enclosed list of references is disclosed so as to comply with the duty of disclosure set forth in 37 C.F.R. § 1.56.

Moreover, while no representation is made that a specific search of office files or patent office records has been conducted or that no better art exists, the undersigned attorney of record believes that

Information Disclosure Statement

Application No. ~~10/703,066~~ 10/703,066

Page 2

the references listed, together with any other references which may have been previously submitted or listed, are the closest to the claimed invention (taken in its entirety) of which the undersigned is presently aware, and no art which is closer to the claimed invention (taken in its entirety) has been knowingly withheld.

☐ In accordance with 37 C.F.R. §§ 1.97 and 1.98, a copy of each listed reference (or relevant portion thereof) which was not previously submitted to, or cited by, the Patent Office is also enclosed.

☒ Legible copies of the listed non-patent literature and foreign documents or their relevant portions. Copies of U.S. patents and/or publications are NOT included pursuant to the Official Gazette Notice, dated Aug. 5, 2003, waiving the requirement of 37 C.F.R. 1.98(a)(2)(i).

☐ The references listed in the accompanying Form PTO-1449 are NOT enclosed because, under 37 C.F.R. § 1.98(d), they were previously cited by or submitted to the Office in application number _____, which is relied upon for an earlier filing date under 35 U.S.C. § 120.

For all listed references that are not either in the English language, or accompanied by a translation into English, a concise explanation of relevance as required under 37 C.F.R. § 1.98(a)(3) is enclosed attached to each.

The Commissioner is hereby authorized to charge any additional fees associated with this communication or to credit any overpayment to Deposit Account No. 20-0100.

Dated this 7th day of May, 2004.

Respectfully submitted,



Gary P. Oakeson
Attorney for Applicant
Registration No. 44,266

THORPE NORTH & WESTERN, LLP
Customer No. 20,551
P.O. Box 1219
Sandy, Utah 84091-1219
Telephone: (801) 566-6633



MWW/JRJ/GPO:ja

Enclosure

H:\FILES\22000\22398\22398 stmt IDS..doc

Sheet 1 of 1

PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 22398	SERIAL NO. 40703-066 10/163,066
LIST OF PRIOR ART CITED BY APPLICANT		APPLICANT Dane J. Dickson	
		FILING DATE Jan. 21, 2004	GROUP 9700-3600

U.S. PATENT DOCUMENTS

EXAMINER INITIALS		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	A1						
	A2						
	A3						
	A4						
	A5						
	A6						
	A7						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIALS		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
	A8						
	A9						
	A10						
	A11						
	A12						

OTHER PRIOR ART (Including Author, Title, Pertinent Pages, Etc.)

/E.S./	A13	Poster: "Randomized Trial of Tamoxifen Alone . . . Cancer Treatment Group Study," by James N. Ingle, et al., published in the year 2000.
/E.S./	A14	Poster: "A Phase II Trial of 7 Days . . . North Central Cancer Treatment Group Study," by R.M. Goldbeg, et al., published in the year 2000.
/E.S./	A15	Poster: "Percutaneous Administration of . . . of Intrahepatic Lesions of Hepatocellular Carcinoma (HCC)," by Phillip J. Johnson, et al., published in the year 2000.
/E.S./	A16	Poster: "Rituximab Following High Dose . . . of a Phase I-II Trial," by S. Horiwitz, et al., published in the year 2000.

EXAMINER /Eliza Squires/	DATE CONSIDERED 01/02/2009
-----------------------------	-------------------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication with applicant.